Diabetes

Concerns that the addition of insulin to type 2 diabetes patients already on the new injectable glucagon-like peptide (GLP-1) liraglutide could result in weight gain may not be warranted, researchers suggested here.

While finding may not be surprising, the question becomes how to intervene to help patients

But Japanese patient population that was the subject of this study has different risk factors compared with other groups

Despite initial worries, gliptins demonstrate cardioprotective effects

Basal plus prandial insulin added to a background regimen of oral antihyperglycemics improves glycemic control in people with poorly controlled type 2 diabetes, researchers reported at the American Diabetes Association annual meeting here.

As the Canadian population ages, pharmacists will be seeing even more patients who may not have only diabetes, but other medical issues as well.

Diabetes: From paper into practice.